Invasive Pneumococcal Disease in New Zealand, 2010
Invasive Pneumococcal Disease in New Zealand, 2010 Invasive Pneumococcal Disease in New Zealand, 2010
ACKNOWLEDGEMENTSPublic Health Unit staff for provision of notification data for their regions.Diagnostic microbiology laboratories throughout New Zealand who participate in the nationallaboratory-based surveillance of invasive pneumococcal disease by referring isolates to ESR.Barbara Bowen, Ushma Desai and Erin Higgins, ESR Antibiotic Reference Laboratory, forantimicrobial susceptibility testing; Heather Davies, ESR Invasive Pathogens Laboratory, forserotyping data; Esther Lim, ESR Health Group, for help with the invasive pneumococcaldisease notification data; and Tim Wood, ESR Health Group, for help with the analysis of theNational Immunisation Register data.Invasive pneumococcal disease September 2011in NZ, 2010
CONTENTSSUMMARY ................................................................................................................................ i1. INTRODUCTION ........................................................................................................... 12. METHODS ....................................................................................................................... 22.1 Surveillance methods ............................................................................................ 22.2 Laboratory methods .............................................................................................. 32.3 Case definition ...................................................................................................... 32.4 Abbreviations ........................................................................................................ 43. RESULTS ......................................................................................................................... 53.1 Laboratory criteria upon which diagnosis based ................................................... 53.2 Disease incidence by age ...................................................................................... 53.3 Disease incidence by season ................................................................................. 83.4 Disease incidence by ethnicity .............................................................................. 93.5 Disease incidence by deprivation ........................................................................ 103.6 Disease presentation, fatalities and hospitalisation ............................................. 113.7 Risk factors among IPD cases ............................................................................. 123.8 Immunisation status of cases ............................................................................... 133.9 Incidence by district health board ....................................................................... 143.10 Serotype distribution ........................................................................................... 153.11 Antimicrobial susceptibility ................................................................................ 194. DISCUSSION ................................................................................................................. 22REFERENCES ........................................................................................................................ 25Appendix 1.Appendix 2.Appendix 3.Appendix 4.Appendix 5.Laboratory criteria upon which invasive pneumococcal disease diagnosisbased, as recorded in the case notification, 2010 ............................................ 27Age distribution among invasive pneumococcal disease cases
- Page 1 and 2: INVASIVE PNEUMOCOCCAL DISEASEIN NEW
- Page 3: DISCLAIMERThis report or document (
- Page 7 and 8: SUMMARYA 4-dose schedule of the 7-v
- Page 9 and 10: 1. INTRODUCTIONPrior to 2009, the n
- Page 11 and 12: Data analyses were performed with S
- Page 13 and 14: 3. RESULTSIn 2010, 535 IPD cases we
- Page 15 and 16: The all-age rate of IPD in 2010 (12
- Page 17: 3.4 Disease incidence by ethnicityT
- Page 20 and 21: 3.7 Risk factors among IPD casesThe
- Page 23 and 24: 3.10 Serotype distributionTable 9.
- Page 25 and 26: Rate per 100 000The rate of disease
- Page 27 and 28: 3.11 Antimicrobial susceptibilityTa
- Page 29 and 30: Percent of penicillin-resistant iso
- Page 31 and 32: type most frequently reported to ha
- Page 33 and 34: REFERENCES1 Green MJ, Cawley PFM. I
- Page 35 and 36: Appendix 1. Laboratory criteria upo
- Page 37 and 38: Appendix 3. Rates of invasive pneum
- Page 39 and 40: Appendix 5.2010Risk factors among i
- Page 41 and 42: Appendix 7. Serotypes among invasiv
- Page 43 and 44: Appendix 9. Serotype 1 invasive pne
- Page 45 and 46: Appendix 11. Trends in penicillin r
- Page 47 and 48: Appendix 13. Penicillin and cefotax
- Page 49: Appendix 15. Trends in penicillin r
CONTENTSSUMMARY ................................................................................................................................ i1. INTRODUCTION ........................................................................................................... 12. METHODS ....................................................................................................................... 22.1 Surveillance methods ............................................................................................ 22.2 Laboratory methods .............................................................................................. 32.3 Case def<strong>in</strong>ition ...................................................................................................... 32.4 Abbreviations ........................................................................................................ 43. RESULTS ......................................................................................................................... 53.1 Laboratory criteria upon which diagnosis based ................................................... 53.2 <strong>Disease</strong> <strong>in</strong>cidence by age ...................................................................................... 53.3 <strong>Disease</strong> <strong>in</strong>cidence by season ................................................................................. 83.4 <strong>Disease</strong> <strong>in</strong>cidence by ethnicity .............................................................................. 93.5 <strong>Disease</strong> <strong>in</strong>cidence by deprivation ........................................................................ 103.6 <strong>Disease</strong> presentation, fatalities and hospitalisation ............................................. 113.7 Risk factors among IPD cases ............................................................................. 123.8 Immunisation status of cases ............................................................................... 133.9 Incidence by district health board ....................................................................... 143.10 Serotype distribution ........................................................................................... 153.11 Antimicrobial susceptibility ................................................................................ 194. DISCUSSION ................................................................................................................. 22REFERENCES ........................................................................................................................ 25Appendix 1.Appendix 2.Appendix 3.Appendix 4.Appendix 5.Laboratory criteria upon which <strong>in</strong>vasive pneumococcal disease diagnosisbased, as recorded <strong>in</strong> the case notification, <strong>2010</strong> ............................................ 27Age distribution among <strong>in</strong>vasive pneumococcal disease cases
Change language